Naju

Researchers are evaluating the drug CMG190303 for treating adults with Type 2 Diabetes and Dyslipidemia. This Phase III trial aims to compare changes in blood sugar control (HbA1c) and cholesterol levels (LDL-C) between CMG190303 and standard treatments Rosuvastatin and Dapagliflozin. The study also focuses on assessing the safety of CMG190303 in this patient population. Participants receive different drug combinations over a 24-week period. One group takes CMG190303, which combines Dapagliflozin and Rosuvastatin with doses increasing every 8 weeks. Another group receives Dapagliflozin with a Rosuvastatin placebo, and a third group receives Rosuvastatin with a Dapagliflozin placebo, with doses also increasing every 8 weeks. This design allows comparison of the investigational drug against standard therapies. Throughout the study, participants undergo assessments including blood tests to monitor HbA1c and LDL-C levels. Researchers track changes from the start of the study to 24 weeks to evaluate treatment effects. Safety is monitored continuously, and medication adherence is checked during run-in periods. The study includes adults aged 19 to 80 years with Type 2 Diabetes and Dyslipidemia, and total participation lasts at least 24 weeks.